0 CHECKOUT

Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2015

  • ID: 3502760
  • October 2015
  • 36 pages
  • Global Markets Direct
1 of 4

Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2015

Summary

The report ‘Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2015’, provides an overview of the Cerebral Infarction (Brain Infarction)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Cerebral Infarction (Brain Infarction) Overview

Therapeutics Development

Pipeline Products for Cerebral Infarction (Brain Infarction) - Overview

Pipeline Products for Cerebral Infarction (Brain Infarction) - Comparative Analysis

Cerebral Infarction (Brain Infarction) - Therapeutics under Development by Companies

Cerebral Infarction (Brain Infarction) - Therapeutics under Investigation by Universities/Institutes

Cerebral Infarction (Brain Infarction) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Cerebral Infarction (Brain Infarction) - Products under Development by Companies

Cerebral Infarction (Brain Infarction) - Products under Investigation by Universities/Institutes

Cerebral Infarction (Brain Infarction) - Companies Involved in Therapeutics Development

Johnson & Johnson

R-Tech Ueno, Ltd.

Shin Nippon Biomedical Laboratories, Ltd.

Cerebral Infarction (Brain Infarction) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CNTO-0007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

epoetin alfa - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptide for Cerebral Infarction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RTU-009 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cerebral Infarction (Brain Infarction) - Recent Pipeline Updates

Cerebral Infarction (Brain Infarction) - Dormant Projects

Cerebral Infarction (Brain Infarction) - Dormant Projects

Cerebral Infarction (Brain Infarction) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cerebral Infarction (Brain Infarction), H2 2015

Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Cerebral Infarction (Brain Infarction) - Pipeline by Johnson & Johnson, H2 2015

Cerebral Infarction (Brain Infarction) - Pipeline by R-Tech Ueno, Ltd., H2 2015

Cerebral Infarction (Brain Infarction) - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Cerebral Infarction (Brain Infarction) Therapeutics - Recent Pipeline Updates, H2 2015

Cerebral Infarction (Brain Infarction) - Dormant Projects, H2 2015

Cerebral Infarction (Brain Infarction) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Cerebral Infarction (Brain Infarction), H2 2015

Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Johnson & Johnson
R-Tech Ueno, Ltd.
Shin Nippon Biomedical Laboratories, Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.